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Available online 13 January 2016Tuberous sclerosis is associatedwith epilepsy in up to 85% of cases, and in 2/3, the onset is within the ﬁrst year of
life. An early antiepileptic treatment is crucial tominimize the consequences of epilepsy on cognition and behav-
ior. We present a case report of a child with tuberous sclerosis who presentedwith infantile spasms at the age of
6 months, immediately treated with vigabatrin. Because of the presence of a subependymal giant cell astrocyto-
ma, he also received everolimus since 18months of age.Wemightwonder if an earlier treatment could have pro-
duced a better outcome; in fact, despite a targeted combined treatment, he continues to suffer from sporadic focal
motor seizures, and at the age of 40months, he presents severe developmental delay with autism-like behavior.








Tuberous sclerosis complex (TSC) is a genetic multisystem disorder
in which benign hamartomas develop in multiple organ systems [1].
The disorder has an estimated birth incidence of 1:5800 [2]. Epilepsy
is the most frequent neurological manifestation in patients affected by
TSC, involving up to 80% of subjects [3]. Epileptic seizures begin in the
ﬁrst year of life in about one-third of TSC patients, and sometimes in
the very ﬁrst weeks of life [4]. Focal seizures may be the ﬁrst seizure
type and may coexist or evolve into infantile spasms [5]. Children with
TSC presenting an early seizure onset are at high risk of developing re-
fractory epilepsy and/or an epileptic encephalopathy; by the age of
2 years, 42% of children with TSC will manifest drug-resistant seizures
[4]. Early life seizures are also associated with a greater incidence of
severe/profound cognitive impairment and autism-like behavior [4,6].
However, cognitive–behavioral disturbancesmight be present indepen-
dently of seizures. Manifestations related to TSC are the consequence of
the hyperactivation of the so-called mTOR (mammalian target of
rapamycin) pathway, resulting from the loss of TSC1 or TSC2 gene, and
leading to abnormalities in cell growth and differentiation, synaptogen-
esis, and impaired protein synthesis [7].hiatry Unit, Systems Medicine
xford 81, 00133 Rome, Italy.
avero).
. This is an open access article underAdeﬁnite clinical diagnosis of TSC can bemade in the presence of two
major features, but identiﬁcation of either a TSC1 or TSC2 pathogenicmu-
tation is sufﬁcient to make a deﬁnite diagnosis too [8]. Cardiac
rhabdomyomas, cortical tubers, subependymal nodules, and renal
angiomyolipomas may be detected by prenatal imaging allowing an
early diagnosis [9,10]. Today, TSC can be diagnosed prenatally, or early
postnatally in a growing number of patients [11], and all the diagnosed
infants should be considered at a high risk of developing early onset sei-
zures [12]. Therefore, clinicians should educate parents to recognize sub-
tle focal seizures or epileptic spasms as early as possible, thus, trying to
reduce the gap between seizure onset and treatment initiation [13–15].
Similarly, all children should be considered at high risk for
neurocognitive and behavioral impairments, and should be regularly
evaluated in order to highlight early signs of deviation from the typical
developmental trajectory so that an early intensive behavioral treat-
ment programcould be applied. In particular, there is still little evidence
whether early treatment with everolimus or combined treatment with
vigabatrin and everolimus is able to reduce the risk of epilepsy and
neurodevelopmental disability.
In this paper, we report the case of a child with TSC and early onset
epilepsy, treated with a combined targeted therapy of vigabatrin and
everolimus, and followed up until the age of 40 months.
1.1. Case presentation
A 3-week-old male newborn came to our attention after the detec-
tion of cardiac rhabdomyomas at 28 weeks of gestational age, and thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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by fetal brain MRI. Hewas born at 32 gestation weeks after an unevent-
ful pregnancy by healthy, nonconsanguineous parents. An early postna-
tal MRI conﬁrmed the TSC diagnosis. Genetic molecular analysis
revealed a de novo mutation on the TSC2 gene (c.687_690del CTGC).
Electroencephalogram monitoring was started at 3 weeks of life and
was continued at 4-week intervals, for the ﬁrst 6 months of life, and
every 6–8 weeks, or as clinically needed thereafter, according to
the recommendations from the European Consensus Conference on
TSC-related epilepsy [14]. During theﬁrst evaluations, his neurologic ex-
amination and thewakefulness and sleep video-EEGwere normal for his
age (Fig. 1A). At the age of 2 months, some isolated sharp waves and
spikes appeared on the left temporal region during sleep (Fig. 1B); thisFig. 1. Sleep EEGs of the patient at different timepoints. A. The ﬁrst EEG at 3weeks of life showed
2months, sleep and awake EEG continued to show a good background organization. Very rare a
of 5 months, the EEG pattern begins to change. Epileptiform abnormalities now become sustain
kind of EEG patternmight be considered as a “point of no return”, afterwhich, a progressive EEG
few weeks. D. Signiﬁcant evolution of the EEG pattern, which now shows recurrent and sustain
with a pseudo-periodism.epileptic focus appeared to be in topographic concordance with a large
left temporal tuber seen byMRI. At the age of 5months, the epileptiform
abnormalities became multifocal, and bilateral temporoparietal slow
waveswere also recorded (Fig. 1C). However, the background EEGactiv-
ity showed a good organization, with regional differentiation and sleep
spindles and K complex during NREM sleep. At the age of 6 months,
the EEG wasmore active, showing recurrent multifocal slowing and ep-
ileptiform abnormalities, with a pseudo-periodism (Fig. 1D). Epilepti-
form abnormalities became more frequent and often generalized, with
epileptic foci mainly localized in the right hemisphere. Starting from
the age of 6 months, serial neuropsychological evaluations were per-
formed every 6 months using the Grifﬁths Mental Developmental
Scale (GMDS). All the single items have been analyzed in full detail toa good background organizationwith no clear epileptiform abnormalities. B. At the age of
nd isolated spikes appeared only during sleep on the left temporal region (T3). C. At the age
ed andmultifocal, with an initial tendency to spread, at least in the same hemisphere. This
deteriorationwith a signiﬁcant increase of epileptiform abnormalities is likely to occur in a
ed epileptiform abnormalities with spikes and spike and waves with a tendency to spread
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structured neuropsychological evaluation revealed a normal develop-
mental quotient (DQ) of 99.
One day, after the child presented subtle spasms, vigabatrin (VGB)
was immediately started and titrated up to 128 mg/kg/day to obtain a
complete cessation of the epileptic spasms and a progressive disappear-
ance of secondary bilateral synchrony on the EEG. After 3 weeks of VGB
treatment, the EEG showed only the persistence of isolated multifocal
sharp waves. The child never presented a hypsarrhythmic EEG pattern.
After spasm cessation, the baby presented good clinical conditions
and continued to be interactive and participative. However, the EEG
showed the persistence of focal slow abnormalities, and the representa-
tion of NREM physiologic elements began to be insufﬁcient. After a
seizure-free period of 5 weeks, focal seizures characterized by psycho-
motor arrest and left eye deviation appeared. Clobazamwas introduced,
initially producing a seizure-free period, but seizures soon appeared
again, and he also began to have daily focal tonic seizures, sometimes
followed bymyoclonic jerks. At the age of 18months, after the detection
of a growth in the size of a subependymal giant cell astrocytoma, evero-
limuswas introduced at an initial dosage of 2.5mg every other day, sub-
sequently increased at 2.5 mg/day due to low blood levels. About one
month after everolimus introduction, the child ceased to have convul-
sive seizures, only showing brief duration psychomotor arrests, with a
global decrease in daily seizure frequency. At the age of 26 months, he
began again have focal motor seizures, and because of the high myo-
clonic component, clobazam was replaced with clonazepam with good
clinical results. He subsequently had three months of seizure freedom,
followed by the reappearance of brief sporadic seizures characterized
by psychomotor arrest.
After the age of 8months, a gradual deceleration of the developmen-
tal trajectorywas observed, conﬁrmed by a decrease in DQ values (99 at
6 months, 71 at 12 months, and below 50 at 18, 24, and 30 months of
age) reﬂecting a lack of acquisitions with a minimal increase of
developmental age over time up to the age of 24 months followed by
a severe regression (Fig. 2). After the age of 12 months, the child
also began to show some autistic traits including alterations in
sociocommunication areas, such as poor eye contact, failure to respond
to name, and deﬁcit of visual and joint attention, associated with pat-
terns of stereotyped and repetitive behaviors. After the second year of
life, a progressive decrease in the functional usage of his hands ap-
peared, worsening the general performances of the child, and severely
inﬂuencing the last neuropsychological evaluation performed at the
age of 30 months. Autism Diagnostic Observation Schedule (ADOS), a
semistructured, interactive schedule designed to assess social and com-
municative functioning, could not be administered to better investigate
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Fig. 2. This chart shows the developmental age of the child over time. After the ﬁrst
evaluation at the age of 6 months, he never appeared to develop according to his
chronological age, and after 1 year without signiﬁcant acquisitions, he signiﬁcantly lost
many abilities.By analyzing in detail the different evolution of the various develop-
mental areas as assessed through GMDS, we detected a slow but contin-
uous gain of acquisition of motor abilities, associated with stagnation in
performance and oculomanual coordination. On the other hand, a clear
regression of developmental age was observed in the areas of hearing
and language, but above all, in the personal–social abilities. In particular,
he lost the social smiling with the mirror from the 12th month of age,
and later, he also ceased to show interest for other persons, to electively
recognize his parents, and to interactively play. Expressive language
was never achieved, and after some months of babbling, he completely
stopped producing sounds.
2. Discussion
To the best of our knowledge, this is the ﬁrst case report of a long-
term follow-up of a child with TSC treated with a targeted combined
treatment, including vigabatrin and everolimus, and carefully evaluated
both from a neurodevelopmental point of view and an electroclinical
point of view. The clinical evolution of this young boy shows that,
even if early VGB treatment might minimize the long-term
neurocognitive outcome, it is not able to totally revert the neurobehav-
ioral phenotype, which is a multifactorial condition [13, 16]. To better
understand this process, it is important to consider that neurocognitive
symptoms and epilepsy in TSC share a common neurobiological causa-
tive pathway, inwhichmTOR overactivation is responsible for an imbal-
ance between excitation and inhibition, as well as for synaptic and
connectivity abnormalities [17]. In particular, experimental data suggest
that mTOR overactivation resulting from loss of TSC1 or TSC2 gene de-
termines abnormal dendritic spines, enhancement of glutamatergic
neurotransmission, as well as a contribution to the reduction of
GABAergic transmission [17]. Although this is not a rule, it is
well known that patients with TSC2 mutations are at higher risk of
earlier onset and more refractory seizures when compared with pa-
tients with TSC1, and that TSC2 is associated with more severe
neurodevelopmental impairment [18]. Furthermore, a higher tuber bur-
den aswell as a greater involvement of whitematter has been shown to
be associated with a more severe neurological phenotype [16,19,20].
Our patient presented several risk factors usually associated with a
worse prognosis. It is becoming increasingly evident that in children
with TSC, the presence of epileptiform discharges before any clinical
symptom should be regarded with caution, since the risk of subsequent
seizures is to be considered 100% [21,22]. The patient showed a negative
cognitive evolution not apparently linked to epilepsy, consequently not
depicting a real epileptic encephalopathy. Indeed, we have to consider
an epileptic encephalopathy as a condition in which cognitive, sensory,
and/or motor functions deteriorate as a consequence of epileptic activ-
ity, which consists of frequent seizures and/or major so-called interictal
paroxysmal activity [23]. However, in this child, a progressive decelera-
tion of acquisitions was noticed after spasm cessation andwith a lack of
major interictal paroxysmal activity, although background organization
progressively worsened over time.
This severe phenotype was present in the child despite promptly re-
ceiving a targeted combined treatmentwith a strong rationale for efﬁca-
cy in TSC. In particular, VGB acts on GABAergic neurotransmission,
while both VGB and everolimus act onmTOR inhibition, thus, providing
a hypothetical wide spectrum treatment for TSC-related seizures and its
comorbidities [12]. Furthermore, clobazamhas also been shown to have
a potential beneﬁt on TSC-related epilepsy [24].
Despite experiencing some seizure-free periods, our patient never
presented adequate psychomotor evolution after the age of 6 months.
Neither the early administration of synergic GABAergic antiepileptic
drugs, nor the addition of mTOR inhibition was able to prevent the evo-
lution toward an encephalopathy inwhich epilepsywas present but did
not appear to be a causative factor.
Themost signiﬁcant open question in this case remains the timing of
treatment. We might wonder if a more precocious treatment with VGB
16 R. Moavero et al. / Epilepsy & Behavior Case Reports 5 (2016) 13–16started right at the beginning of multifocal epileptiform abnormalities,
and/or an earlier start of everolimus could have been able to lead to-
ward a less severe neurocognitive phenotype. Our clinical experience
also suggests that this risk is much higher when multifocal abnormali-
ties and a tendency toward generalization occur.
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